Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Cross-Sectional Study

Comparison between the ECG Outcomes of Metoprolol and Bisoprolol

Author(s): Ahmad Abdulrahman Almeman*, Yousef Obaid Alharbi*, Abdulaziz Sulaiman Alwahhabi, Abdulaziz Abdullah Almutairi, Moayad Yousef Alnasr and Abdulrahaman Almesnid

Volume 22, Issue 4, 2024

Published on: 31 October, 2023

Page: [503 - 507] Pages: 5

DOI: 10.2174/0118715257252349231018151957

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Beta-blockers are essential agents in the management of cardiovascular diseases, such as heart failure, acute myocardial infarction (MI), and cardiac arrhythmias. However, there are diurnal variations in the cardioprotective effects of the subgroups as a result of their different pharmacokinetic, pharmacodynamic, and pharmacogenetic profiles.

Objectives: We aimed to compare metoprolol and bisoprolol in terms of electrocardiogram (ECG) outcomes.

Methods: A retrospective cross-sectional study was conducted at Prince Sultan Cardiac Center. The trial included 404 patients who met the inclusion criteria (204 in the metoprolol arm and 200 in the bisoprolol arm). Using case record forms that had already been created, information, such as patient demographics, medical histories, and treatment histories, was taken from their medical files. The most recent ECG records were also gathered. The ethical approval for this study was obtained from Qassim ethical committee (approval number: 45-44-902).

Results: There was no significant difference found between the patients in both arms in terms of baseline characteristics, age, or sex.

Conclusion: In this retrospective cross-sectional study, we have compared the effects of metoprolol and bisoprolol beta blockers on ECG changes. The findings have indicated no difference between metoprolol and bisoprolol groups in terms of all ECG readings, particularly PR/ms, QTC-ms, and ventricular rate. Further studies are required to confirm these findings.

Keywords: Beta-blockers, cardiovascular diseases, metoprolol, bisoprolol, ECG, pharmacogenetics.

[1]
Jaïs, P.; Cauchemez, B.; Macle, L.; Daoud, E.; Khairy, P.; Subbiah, R.; Hocini, M.; Extramiana, F.; Sacher, F.; Bordachar, P.; Klein, G.; Weerasooriya, R.; Clémenty, J.; Haïssaguerre, M. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation, 2008, 118(24), 2498-2505.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.772582] [PMID: 19029470]
[2]
Wong, G.W.K.; Boyda, H.N.; Wright, J.M. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Libr., 2016, 2016(4), CD007451.
[http://dx.doi.org/10.1002/14651858.CD007451.pub2] [PMID: 26961574]
[3]
Wong, G.W.K.; Wright, J.M. Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension. Cochrane Libr., 2014, (2), CD007452.
[http://dx.doi.org/10.1002/14651858.CD007452.pub2] [PMID: 24585007]
[4]
Bennett, M.T.; Gula, L.J.; Klein, G.J.; Skanes, A.C.; Yee, R.; Leong-Sit, P. Effect of beta-blockers on QT dynamics in the long QT syndrome: measuring the benefit. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias. Card Cell Electrophysiol Eur Soc Cardiol., 2014, 16(12), 1847-1851.
[5]
Fröhlich, H.; Torres, L.; Täger, T.; Schellberg, D.; Corletto, A.; Kazmi, S.; Goode, K.; Grundtvig, M.; Hole, T.; Katus, H.A.; Cleland, J.G.F.; Atar, D.; Clark, A.L.; Agewall, S.; Frankenstein, L. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin. Res. Cardiol., 2017, 106(9), 711-721.
[http://dx.doi.org/10.1007/s00392-017-1115-0] [PMID: 28434020]
[6]
Escoubet, B.; Leclercq, J.F.; Maison-Blanche, P.; Poirier, J.M.; Gourmel, B.; Delhotal-Landes, B.; Coumel, P. Comparison of four beta-blockers as assessed by 24-hour ECG recording. Clin. Pharmacol. Ther., 1986, 39(4), 361-368.
[http://dx.doi.org/10.1038/clpt.1986.55] [PMID: 3956052]
[7]
FDA. LOPRESSOR (metoprolol tartrate) tablet. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017963s062,018704s021lbl.pdf (accessed on: 2023 Feb 12).
[8]
FDA. ZEBETA (bisoprolol fumarate) tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf (accessed on: 2023 Feb 12).
[9]
Wilk, J.B.; Myers, R.H.; Pankow, J.S.; Hunt, S.C.; Leppert, M.F.; Freedman, B.I.; Province, M.A.; Ellison, R.C. Adrenergic receptor polymorphisms associated with resting heart rate: the HyperGEN Study. Ann. Hum. Genet., 2006, 70(5), 566-573.
[http://dx.doi.org/10.1111/j.1469-1809.2005.00258.x] [PMID: 16907703]
[10]
Kong, H.; Li, X.; Zhang, S.; Guo, S.; Niu, W. The β1-adrenoreceptor gene Arg389Gly and Ser49Gly polymorphisms and hypertension: a meta-analysis. Mol. Biol. Rep., 2013, 40(6), 4047-4053.
[http://dx.doi.org/10.1007/s11033-012-2482-2] [PMID: 23271137]
[11]
Pacanowski, M.A.; Gong, Y.; Cooper-DeHoff, R.M.; Schork, N.J.; Shriver, M.D.; Langaee, T.Y.; Pepine, C.J.; Johnson, J.A. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther., 2008, 84(6), 715-721.
[http://dx.doi.org/10.1038/clpt.2008.139] [PMID: 18615004]
[12]
Bijl, M.J.; Visser, L.E.; van Schaik, R.H.N.; Kors, J.A.; Witteman, J.C.M.; Hofman, A.; Vulto, A.G.; van Gelder, T.; Stricker, B.H.C. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin. Pharmacol. Ther., 2009, 85(1), 45-50.
[http://dx.doi.org/10.1038/clpt.2008.172] [PMID: 18784654]
[13]
Dean, L. Thioridazine Therapy and CYP2D6 Genotypes; Pratt, V.M.; Scott, S.A.; Pirmohamed, M.; Esquivel, B.; Kattman, B.L.; Malheiro, A.J., Eds.; Bethesda, MD, 2012.
[14]
Meloche, M.; Khazaka, M.; Kassem, I.; Barhdadi, A.; Dubé, M.P.; Denus, S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis. Br. J. Clin. Pharmacol., 2020, 86(6), 1015-1033.
[http://dx.doi.org/10.1111/bcp.14247] [PMID: 32090368]
[15]
Yang, T.; Jiang, Y.; Hao, Y.; Zhou, S.; Xu, X.; Qu, B.; Lin, X.; Ma, T. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens. Res., 2017, 40(1), 79-86.
[http://dx.doi.org/10.1038/hr.2016.101] [PMID: 27534738]
[16]
AlHabeeb, W.; Mrabeti, S.; Abdelsalam, A.A.I. Therapeutic properties of highly selective β-blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease. Cardiovasc. Drugs Ther., 2022, 36(5), 959-971.
[http://dx.doi.org/10.1007/s10557-021-07205-y] [PMID: 34106365]
[17]
Joannides, R.; Moore, N.; Iacob, M.; Compagnon, P.; Lerebours, G.; Menard, J.F.; Thuillez, C. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br. J. Clin. Pharmacol., 2006, 61(2), 127-137.
[http://dx.doi.org/10.1111/j.1365-2125.2005.02544.x] [PMID: 16433867]
[18]
Chockalingam, P.; Crotti, L.; Girardengo, G.; Johnson, J.N.; Harris, K.M.; van der Heijden, J.F.; Hauer, R.N.W.; Beckmann, B.M.; Spazzolini, C.; Rordorf, R.; Rydberg, A.; Clur, S.A.B.; Fischer, M.; van den Heuvel, F.; Kääb, S.; Blom, N.A.; Ackerman, M.J.; Schwartz, P.J.; Wilde, A.A.M. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J. Am. Coll. Cardiol., 2012, 60(20), 2092-2099.
[http://dx.doi.org/10.1016/j.jacc.2012.07.046] [PMID: 23083782]
[19]
Mesquita, E.T.; Deus, F.C.C.; Guedes, C.R.; Maia, E.R.; Subieta, C.G.P.; Villacorta, H.; Santos, P.A.; Cramer, H.; Santos, V.B.A.; Romeo, L.J.M. Effects of propranolol on the QT dispersion in congestive heart failure. Arq. Bras. Cardiol., 1999, 73(3), 295-298.
[http://dx.doi.org/10.1590/S0066-782X1999000900005] [PMID: 10754584]
[20]
Nozawa, T.; Taguchi, M.; Tahara, K.; Hashimoto, Y.; Igarashi, N.; Nonomura, M.; Kato, B.; Igawa, A.; Inoue, H. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J. Cardiovasc. Pharmacol., 2005, 46(5), 713-720.
[http://dx.doi.org/10.1097/01.fjc.0000184117.76188.68] [PMID: 16220080]
[21]
Leopold, G. Balanced pharmacokinetics and metabolism of bisoprolol. J. Cardiovasc. Pharmacol., 1985, 8(Suppl. 11), S16-S20.
[http://dx.doi.org/10.1097/00005344-198511001-00003] [PMID: 2439789]
[22]
Zisaki, A.; Miskovic, L.; Hatzimanikatis, V. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr. Pharm. Des., 2014, 21(6), 806-822.
[http://dx.doi.org/10.2174/1381612820666141024151119] [PMID: 25341854]
[23]
Ingram, A.; Valente, M. Genetic variation of hepatic enzymes influence on β-blocker dose in patients with reduced ejection fraction heart failure. J. Pharm. Pract., 2020, 33(1), 96-98.
[http://dx.doi.org/10.1177/0897190018782794] [PMID: 29916290]
[24]
Newton, G.E.; Parker, J.D. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation, 1996, 94(3), 353-358.
[http://dx.doi.org/10.1161/01.CIR.94.3.353] [PMID: 8759076]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy